A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

Halozyme (HALO) filed a patent infringement lawsuit against Merck (MRK) in U.S. District Court in New Jersey. Halozyme believes the ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...